After 1200 clinical trials testing potential COVID-19 drugs, the US still has no clear answers. Many trials have enrollment and recruitment numbers that are too small for meaningful results. “If we had taken the U.K.’s strategy of a set of large pragmatic trials, prioritizing recruitment in those trials, we could have all the answers now that we’re waiting for,” CP3 Director Dr. Walid Gellad told STAT.